Notox Technologies (NTOX) 10-K 14 Dec 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - CAD ($)	12 Months Ended
	Aug. 31, 2018	Dec. 14, 2018	Feb. 28, 2018
Document And Entity Information
Entity Registrant Name	NOTOX TECHNOLOGIES CORP.
Entity Central Index Key	844,538
Document Type	10-K
Amendment Flag	false
Document Period End Date	Aug. 31, 2018
Current Fiscal Year End Date	--08-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 14,312,402
Entity Common Stock Shares Outstanding		57,545,343
Trading Symbol	TRPO
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets

Consolidated Balance Sheets - CAD ($)	Aug. 31, 2018	Aug. 31, 2017
Current assets:
Cash	$ 5,664	$ 63,144
Amounts receivable	72,301	84,290
Inventory (Note 8)		1
Prepaid expenses	24,048	28,624
Total current assets	102,013	176,059
Equipment, net (Note 7)		34,197
Patents, net (Note 8)	4	4
License agreement, net (Notes 3 and 9)	1,124,799	1,312,265
Total assets	1,226,816	1,522,525
Current liabilities:
Accounts payable and accrued liabilities (Notes 10 and 11)	1,582,691	1,075,601
Advances from related parties/shareholders (Notes 11 and 12)	477,509	415,960
License assignment fee and accrued interest payable (Notes 3 and 13)	882,257	683,212
Stock purchase warrants (Notes 4 and 15)	353,517	297,378
Stock subscribed (Note 15)	10,000	838,674
Total current liabilities	3,305,974	3,310,825
Due to the Clinic (Note 3)	227,707	197,765
Total liabilities	3,533,681	3,508,590
Stockholders' deficiency (Note 15):
Common stock	1,018,256	526,182
Additional paid-in capital	8,458,365	8,460,414
Deficit	(11,783,486)	(10,972,661)
Total stockholders' deficiency	(2,306,865)	(1,986,065)
Total liabilities and stockholders' deficiency	$ 1,226,816	$ 1,522,525

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - CAD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Aug. 31, 2016
Revenue:
Sales			$ 863
Production costs:
Amortization - license agreement (Note 9)	187,466	187,466
Amortization - patent (Note 8)		376,423	374,228
Consulting fees - production	2,820	27,700	31,200
Depreciation (Note 7)	5,129	8,550	10,687
Design and production - NRFTS		143,153
Materials and supplies		960	10,071
Patenting costs - the Clinic (Note 3)	21,201	197,765
Writedown of inventory (Note 8)	1	122,101	365
Total production costs	216,617	1,064,118	426,551
Gross loss	(216,617)	(1,064,118)	(425,688)
General and administration:
Consulting fees - management (Note 11)	384,829	507,004	422,706
Interest on advances from related parties/shareholders (Notes 11 and 12)	10,549	11,351	12,434
Interest on license assignment fee payable (Note 13)	167,123
Investor relations		732
Loss (gain) on foreign exchange	64,439	(68,039)	3,558
Marketing	447	2,248	9,007
Office and miscellaneous	12,407	22,056	21,934
Patent maintenance fees	1,653	7,666
Professional fees	105,744	82,873	81,929
Rent	25,918	12,950	13,200
Travel and entertainment	6,331	23,000	12,417
Trust and filing fees	24,016	13,367	20,627
Total general and administration	803,456	615,208	597,812
Loss before other items and income taxes	(1,020,073)	(1,679,326)	(1,023,500)
Other items:
Gain on revaluation of warrants	286,075	9,333
Writedown of amounts receivable	(49,755)	(20,332)
Loss on disposal of equipment (Note 7)	(29,068)
Recovery of inventory written down	1,996
Writedown of patents (Note 8)		(3,381,362)	(6,793)
Loss before income taxes	(810,825)	(5,071,687)	(1,030,293)
Income taxes
Net loss and comprehensive loss	$ (810,825)	$ (5,071,687)	$ (1,030,293)
Net loss per share - basic and diluted (Note 5)	$ (0.01)	$ (0.09)	$ (0.06)
Weighted-average number of shares outstanding	57,520,185	56,606,971	16,924,423

Consolidated Statements of Cash

Consolidated Statements of Cash Flows	12 Months Ended
	Aug. 31, 2018CAD ($)	Aug. 31, 2017CAD ($)	Aug. 31, 2017USD ($)	Aug. 31, 2016CAD ($)	Aug. 31, 2016USD ($)
Cash Flows Used In Operating Activities
Net loss	$ (810,825)	$ (5,071,687)		$ (1,030,293)
Adjustments to reconcile net loss to net cash provided by operating activities:
Amortization - license agreement	187,466	187,466
Amortization - patent		376,423		374,228
Depreciation	5,129	8,550		10,687
Unrealized foreign exchange on license assignment fee payable	28,285
Unrealized foreign exchange on license assignment fee payable interest payable	3,637
Unrealized foreign exchange on due to the Clinic	8,741
Writedown of amounts receivable	49,755	20,332
Writedown of inventory	1	122,101		365
Loss on disposal of equipment	29,068
Writedown of patents		3,381,362		6,793
Gain on revaluation of warrants	(286,075)	(9,333)
Changes in assets and liabilities:
Amounts receivable	(37,766)	(28,884)		(72,057)
Inventory		216		8,019
Prepaid expenses	4,576	(25,324)
Accounts payable and accrued liabilities	507,090	237,611		520,658
Due to the Clinic	21,201	197,765
Interest accrued on advances from related parties/shareholders	10,549	11,351		12,434
Interest accrued on license assignment fee payable	167,123
Net cash used in operating activities	(112,045)	(592,051)		(169,166)
Cash Flows Used In Investing Activities
Patent costs		(2,090)		(14,949)
License agreement		(663,788)
Cash transferred upon acquisition of Notox				131
Net cash used in investing activities		(665,878)		(14,818)
Cash Flows Provided By Financing Activities
Proceeds from issuance of common stock		395,580
Stock issue costs	(6,435)	(19,899)
Stock subscriptions received	10,000	838,674		315,366
Advances from related parties/shareholders	51,000			5,000
Repayment of advances from related parties/shareholders		(38,000)
Net cash provided by financing activities	54,565	1,176,355		320,366
Increase (decrease) in cash during the year	(57,480)	(81,574)		136,382
Cash, beginning of year	63,144	144,718		8,336
Cash, end of year	$ 5,664	$ 63,144		$ 144,718

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical)	Sep. 07, 2017CAD ($)shares	Nov. 02, 2016CAD ($)shares	Aug. 31, 2017CAD ($)shares	Nov. 23, 2016CAD ($)	Nov. 23, 2016USD ($)
License assignment fee payable			$ 683,212
License Agreement [Member] | Zoran Holding Corporation [Member]
License assignment fee payable				$ 1,347,000
License Agreement [Member] | Zoran Holding Corporation [Member] | USD Currency [Member]
License assignment fee payable					$ 1,000,000
Warrant [Member]
Common stock shares issued during period | shares	5,000	15,000
Purchase warrant, value	$ 2,581	$ 8,742
Stock Subscriptions [Member]
Common stock shares issued during period | shares			838,674

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficiency) - CAD ($)		Common Stock [Member]	Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Deficit [Member]	Total
Balance at Aug. 31, 2015		$ 12,612	$ 30,000	$ 8,431,728	$ (4,870,681)	$ 3,603,659
Balance, shares at Aug. 31, 2015	[1]	6,132,073
Stock subscribed			315,366			315,366
Stock issued for asset acquisition (Notes 3)		$ 127,920				127,920
Stock issued for asset acquisition (Notes 3), shares	[1]	50,000,000
Net loss					(1,030,293)	(1,030,293)
Balance at Aug. 31, 2016		$ 140,532	345,366	8,431,728	(5,900,974)	3,016,652
Balance, shares at Aug. 31, 2016	[1]	56,132,073
Stock issued for cash		$ 414,291	(345,366)	28,686		97,611
Stock issued for cash, shares	[1]	760,770
Stock issue costs - cash		$ (19,899)				(19,899)
Stock issue costs - finder's warrants		(8,742)				(8,742)
Net loss					(5,071,687)	(5,071,687)
Balance at Aug. 31, 2017		$ 526,182		8,460,414	(10,972,661)	(1,986,065)
Balance, shares at Aug. 31, 2017	[1]	56,892,843
Stock issued for cash		$ 491,041				491,041
Stock issued for cash, shares	[1]	630,000
Stock issue costs - cash		$ (6,435)				(6,435)
Stock issue costs - finder's warrants		(2,581)				(2,581)
Warrants exercised		$ 10,049		(2,049)		8,000
Warrants exercised, shares	[1]	10,000
Net loss					(810,825)	(810,825)
Balance at Aug. 31, 2018		$ 1,018,256		$ 8,458,365	$ (11,783,486)	$ (2,306,865)
Balance, shares at Aug. 31, 2018	[1]	57,532,843
[1]	The above presentation reflects a 1:2 reverse split of the Company's common stock on August 25, 2016. See Note 16.

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficiency) (Parenthetical)	Aug. 25, 2016
Statement of Stockholders' Equity [Abstract]
Reverse split	1:2 reverse split

Company Overview and Basis of P

Company Overview and Basis of Presentation	12 Months Ended
	Aug. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company Overview and Basis of Presentation	1. Company Overview and Basis of Presentation Nature and History of Operations Notox Technologies Corp. (formerly Tropic International Inc.) (the “Company”) was incorporated under the laws of the state of Nevada on October 29, 2007. The Company was a natural resource exploration company with an objective of acquiring, exploring and, if warranted and feasible, developing natural resource properties. Activities during the exploration stage included developing the business plan and raising capital. On June 28, 2013, the Company completed a reverse takeover transaction (see Note 2) with Tropic Spa Inc. (“TSI”), a company that manufactures and sells Home Mist Tanning units that deliver a full-body application. As a result of this transaction, the Company became a holding company operating through TSI. Upon the closing of the share exchange agreement described below, the Company changed its fiscal year end from October 31 to August 31 to coincide with the fiscal year end of TSI. On December 6, 2013, the Company changed its name to Tropic International Inc. as a result of a merger with a wholly-owned subsidiary incorporated solely to effect the name change. On November 19, 2018, the Company again changed its name to Notox Technologies Corp. See Note 20. On September 3, 2014, the Company’s shares became eligible for quotation on the OTCQB under the symbol TRPO. On June 13, 2016, the Company completed an asset acquisition transaction (see Note 3) with Notox Bioscience Inc. (“Notox”), a private Nevada corporation incorporated on May 31, 2016 for the purpose of acquiring 100% of the right, title and interest in and to an exclusive license agreement (the “License Agreement”) with The Cleveland Clinic Foundation (the “Clinic”), an Ohio not-for-profit corporation. As a result of this transaction, the Company is a holding company operating through both TSI and Notox. On November 19, 2007, TSI obtained the rights to the Home Mist Tanning system and the application for and acquisition of a United States Patent “Apparatus for Spray Application of a Sunless Tanning Product” On October 16, 2014, the Company, through TSI, obtained an Australian patent (the “Australian Patent”), incurring application costs of $4,976. On June 21, 2016, the Company, through TSI, obtained a Canadian patent (the “Canadian Patent”), incurring application costs of $17,406. On December 28, 2016, the Company, through TSI, obtained a Chinese patent (the “Chinese Patent”), incurring application costs of $5,806. Costs incurred are recorded as intangible assets. On August 31, 2017, the net carrying amount of the patents was written down to a nominal amount of $4 (see Note 8). As reflected in the accompanying consolidated financial statements, the Company has a deficit of $11,783,486 (August 31, 2017 - $10,972,661) since inception, a working capital deficiency of $3,203,961 (August 31, 2017 - $3,134,766) and a stockholders’ deficiency of $2,306,865 (August 31, 2017 - $1,986,065). This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on its ability to raise additional capital and to implement its business plan. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management has evaluated the Company’s ability to continue as a going concern by assessing its ability to meet its obligations as they become due within one year from the date of issue of the financial statements. Management’s assessment included the following factors: ● The Company’s financial condition as at the date of issue of the financial statements; ● The Company’s actual or anticipated conditional and unconditional obligations due within one year from the date of issue of the financial statements; ● The funds necessary to maintain the Company’s operations considering its current financial condition, obligations and other expected cash flows; and ● Other conditions and events that may affect the Company’s ability to meet its obligations within one year from the date of issue of the financial statements. The Company’s operating expenses are estimated to be approximately $100,000 per year. As at August 31, 2018, the Company’s current cash liabilities total approximately $2,942,000 (August 31, 2017 - $2,175,000). Of this amount, approximately $2,607,000 – accounts payable and accrued liabilities ($1,248,000), advances from related parties/shareholders ($477,000) and license assignment fee payable ($882,000) – is payable to related parties and/or major shareholders who have not and will not require payment until such time as sufficient cash flow is available. To the extent the remaining $335,000 cannot be deferred and sufficient equity financing has not been raised to make the payment required, management will advance funds to the Company, if appropriate. The Company’s CEO and President have committed to providing financing if and when necessary to fund the Company’s estimated $100,000 cash operating expenses for the year ended August 31, 2019.

Reverse Takeover

Reverse Takeover	12 Months Ended
	Aug. 31, 2018
Business Combinations [Abstract]
Reverse Takeover	2. Reverse Takeover On June 28, 2013 (the “Closing Date”), the Company, its wholly-owned subsidiary 1894632 Ontario Inc. (“Subco”) and TSI entered into a share exchange agreement (the “Exchange Agreement”) with certain of the shareholders of TSI (the “Selling Shareholders”) pursuant to which the Company acquired 39,015,439 common shares, or approximately 78% of the issued and outstanding shares, of TSI in exchange for the issuance of 39,015,439 preferred shares of Subco to the Selling Shareholders on a one-for-one basis. Each one preferred share of Subco is exchangeable into one share of the Company’s common stock at the option of the holder subject to the following restrictions: ● The Selling Shareholders required the written consent of Subco to exchange, sell or otherwise dispose of, directly or indirectly, any of their preferred shares of Subco until the six month anniversary of the Closing Date; ● Within 30 days of that time, and provided TSI generated at least $1,000,000 in gross revenue during the preceding six month period, Subco permitted the Selling Shareholders to require Subco to redeem an aggregate of 1% of its then-outstanding preferred shares on a pro-rata basis; and ● Within 30 days of each six month anniversary of the Closing Date until June 30, 2015, on which date all restrictions on the preferred shares automatically expired unless extended by the Selling Shareholders, Subco granted the holders of its preferred shares a permission identical to the one above. Upon the closing of the Exchange Agreement, the sole officer and director of TSI became the sole officer and a director of the Company and the Company adopted the business plan of TSI. As a result of the share exchange, the Selling Shareholders controlled approximately 87% of the issued and outstanding common shares of the Company on a fully-exchanged basis as of the Closing Date. The Exchange Agreement represented a reverse takeover and was therefore accounted for under the acquisition method with TSI as the accounting acquirer and continuing entity for accounting and financial reporting purposes and the Company as the legal parent being the acquiree. There was no active market to reliably determine fair value of the consideration other than the value of the identifiable assets acquired. Therefore, the purchase price allocation of the acquisition was based on the fair value of the net liabilities acquired which was charged to additional paid-in-capital. The fair values of assets acquired and liabilities assumed were as follows: Cash $ 1,774 Subscriptions receivable 10 Accounts payable and accrued liabilities (32,488 ) Loan payable to TSI (25,454 ) Net liabilities acquired $ (56,158 ) On February 17, 2015, the Company, Subco, TSI and the Selling Shareholders entered into an amendment to the Exchange Agreement in order to correct certain administrative errors in the Exchange Agreement and provide for the post-closing execution of the Exchange Agreement by those shareholders of TSI who were not original signatories thereto. In addition, the Selling Shareholders approved certain changes to the rights, privileges, restrictions and conditions attached to the preferred shares of Subco by consent in writing. This included extending the automatic expiration date in respect of the preferred shares of Subco from June 30, 2015 to June 30, 2017. On February 22, 2017, this automatic expiration date was further extended to December 31, 2018.

Asset Acquisition and License A

Asset Acquisition and License Agreement	12 Months Ended
	Aug. 31, 2018
Business Combinations [Abstract]
Asset Acquisition and License Agreement	3. Asset Acquisition and License Agreement On June 13, 2016 (the “Second Closing Date”), the Company, Notox and the shareholders of Notox (the “Notox Shareholders”) entered into a share exchange agreement (the “Share Exchange Agreement”) pursuant to which the Company acquired 100% of the issued and outstanding common stock of Notox from the Notox Shareholders in exchange for the issuance of 50,000,000 shares of the Company’s common stock. On the Second Closing Date, Notox and Zoran Holding Corporation (“ZHC”), a private Ontario corporation, entered into an assignment agreement (the “Assignment Agreement”) pursuant to which ZHC irrevocably assigned 100% of its right, title and interest in and to the License Agreement, as amended, to Notox. Also on the Second Closing Date, the sole officer and director of Notox and ZHC became a director and officer of the Company. On November 23, 2016, the Company, Notox and the Notox Shareholders entered into an amendment to the Share Exchange Agreement in order to clarify certain sections in the Share Exchange Agreement, to provide for an assignment fee and to describe how the Company will use the proceeds of any equity financing completed after the Second Closing Date. In consideration for inducing ZHC to enter into the Assignment Agreement, the Company agreed to pay an aggregate of US$1,000,000 to ZKC in the form of a one-time assignment fee. See Note 13. On December 1, 2012, ZHC and the Clinic entered into the License Agreement whereby the Clinic granted ZHC an exclusive worldwide license and a non-exclusive worldwide license in the field of aesthetics and pain to make, use, offer to sell, sell and import certain products throughout the term of the License Agreement. The term continues until the expiration of the last to expire of certain patents. The License Agreement was amended on July 30, 2013 and July 1, 2016. Pursuant to the License Agreement, as amended, Notox is the licensee under the License Agreement and is solely responsible for making all regulatory filings and securing regulatory approval for the products covered by the License Agreement. The Clinic will receive a royalty based on the sale of certain products, a milestone payment within 30 days following the first commercial sale of such products and a percentage of any sublicensing revenues. Royalties and other payments are payable quarterly. Notox is required to achieve two commercial milestones: regulatory filings submitted to regulatory authorities by November 30, 2019 and first commercial sale within nine months following regulatory approval. Failure to achieve these milestones, without satisfactory justification, constitutes a material breach of the License Agreement giving the Clinic the right, but not the obligation, to convert the License Agreement to a non-exclusive license or terminate the License Agreement. The Clinic has the right to verify Notox’s compliance with the License Agreement. Within 30 days following Notox’s receipt of the first regulatory approval, Notox is required to reimburse the Clinic for current patenting costs. All patenting costs, patent office fees and outside patent counsel costs will, at the Clinic’s option, either be paid directly by Notox or by the Clinic with the Clinic invoicing Notox, provided that Notox has no obligation to pay or reimburse the Clinic until after first regulatory approval has been obtained. Upon termination or expiration of the License Agreement, all accrued and unreimbursed patenting costs become immediately due and payable to the Clinic. As of August 31, 2018, all accrued and unreimbursed patenting costs totalled US$174,421 ($227,707) (August 31, 2017 - US$157,758 ($197,765)). As a result of the share exchange and on the Second Closing Date, the Notox Shareholders controlled approximately 89% of the issued and outstanding common stock of the Company (52.5% on a fully-exchanged basis) and Notox became a wholly-owned subsidiary of the Company. Notox did not meet the definition (inputs, processes and outputs criteria) of a business. The Share Exchange Agreement represented an asset acquisition and was therefore accounted for under the asset acquisition method. Acquired intangible assets are recognized and initially measured based on their fair value plus transaction costs incurred as part of the acquisition. There was no active market to reliably determine the fair value of the License Agreement acquired. Therefore, the fair value of the License Agreement was based on the par value of the common stock exchanged by the Company. The fair value and gross carrying value of the License Agreement is as follows: License Agreement $ 133,212 Cash 131 Accrued liabilities (5,423 ) Capital stock exchanged (50,000,000 shares at US$0.002 per share) $ 127,920 Fair value of License Agreement $ 133,212 Acquisition costs 19,519 Assignment fee (US$1,000,000) 1,347,000 Gross carrying value of License Agreement $ 1,499,731 See Note 9.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Aug. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the financial statements of the Company, TSI, Notox, Subco and 1894631 Ontario Inc., the Company’s subsidiaries. All significant inter-company balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to equipment, fair values of intangible assets, useful lives of intangible assets and the likelihood of realization of its deferred tax assets . Concentration of Risk The financial instrument which potentially subjects the Company to a concentration of credit risk is cash. The Company places its cash in an account with a high credit quality financial institution. Significant Accounting Policies The accompanying consolidated financial statements reflect the application of certain significant accounting policies. There have been no material changes to the Company’s significant accounting policies that are disclosed in the consolidated financial statements and notes thereto during the period ended August 31, 2018. Inventory Inventory is stated at the lower of cost, computed using the first-in, first-out method, or market. If the cost of inventory exceeds its market value, a provision is made currently for the difference between the cost and market value. Equipment, Net Equipment is stated at cost, net of accumulated depreciation. Equipment is depreciated over the estimated useful life of the asset. Mould equipment is depreciated at 20% on a declining-balance basis. The website was depreciated on a straight-line basis over five years. One-half of these rates are used in the year of acquisition. Replacements and major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Upon retirement or sale, the cost of assets disposed of and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is credited or charged to operations. Intangible Assets Patents The US Patent is recorded at the value attributed to the shares issued by TSI in connection with its acquisition less accumulated amortization and impairment writedowns. The US Patent was issued on September 29, 2009 and is effective until September 29, 2026. The Australian, Canadian and Chinese Patents are recorded at the application costs incurred less accumulated amortization and impairment writedowns. The Australian Patent was issued on October 16, 2014 and is effective until April 5, 2027. The Canadian Patent was issued on June 21, 2016 and is effective until April 5, 2027. The Chinese Patent was issued on December 28, 2016 and is effective until February 1, 2033. Upon expiration, the patents can be extended subject to certain changes required to secure the extension. Although the effects of obsolescence, demand, competition and other economic factors (such as stability of the industry, technological advances and legislative action that results in an uncertain or changing regulatory environment) can have an adverse effect on the industry and saleability of patented products, management is not currently aware of any known adverse factors that will affect the patents in the future. Costs incurred for patents which are in the process of being completed will be amortized over the life of the patent when the patent is issued. At the time that the patents were issued, the Company did not believe that there were any limits to how long the Home Mist Tanning units could sell in the market place. Accordingly, management had determined that the best estimates of useful lives of the US, Australian, Canadian and Chinese Patents were 17, 13, 11 and 16 years, respectively. At this time, the Company does not believe that the patents will have a residual value at the end of their useful lives. License Agreement The License Agreement is recorded at estimated fair value plus acquisition costs less accumulated amortization and impairment writedowns. The term of the License Agreement continues until the expiration of the last to expire of the Licensed Patents (as defined in the License Agreement). All costs related to the development of the licensed technology are expensed as incurred. The technology licensed by Notox is a platform that provides the Company access to four large market segments or verticals (derma, pain, body and headache) that include the fields of aesthetics, drug-free pain management, body contouring and perspiration control. Based on management’s experience, it takes approximately two years to fully develop each vertical, with each vertical being developed in sequence. Accordingly, management’s best estimate of the amortization period for the License Agreement is eight years. Amortization and Impairment Definite-lived intangible assets are required to be amortized using a method that reflects the pattern in which the economic benefits of the intangible assets are consumed or utilized. Management was not able to determine with any amount of certainty the number of Home Mist Tanning units that would be sold over the useful lives of the patents. Accordingly, the patents were being amortized on a straight-line basis over the period of their useful lives. The License Agreement is being amortized over eight years based on management’s best estimate of the time required to develop the four verticals as explained above. Intangible assets subject to amortization are required to be reviewed for impairment. An impairment loss must be recognized if the intangible asset’s carrying amount is not recoverable and the carrying amount exceeds fair value. The Company applies the following three-step process to identify, recognize and measure impairment of intangible assets: ● Consider whether indicators of impairment are present indicating that the intangible assets’ carrying amount might not be recoverable; ● If indicators are present, perform a recoverability test by comparing the sum of the estimated undiscounted future cash flows attributable to the intangible assets to their carrying amounts; and ● If the undiscounted cash flows used in the recoverability test are less than the intangible assets’ carrying amount, determine the intangible assets’ fair value and recognize an impairment loss if the carrying amount exceeds fair value. Because of the unique nature of a patent and a license agreement, income-producing definite-lived intangible assets, the calculation of cash flows can be very difficult to estimate. In this case, the estimated cash flows reflect the direct revenue expected to be generated by the License Agreement as well as an allocation of expenses. Leases The Company currently rents premises pursuant to an operating lease. Impairment of Long-Lived Assets Long-lived assets, including equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount should be evaluated. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds its fair value. Stock Purchase Warrants When the Company undertakes a private placement, it may issue units comprised of common stock of the Company and warrants to acquire common stock of the Company. Warrants with a strike price denominated in the Company’s functional currency (the Canadian dollar) are considered to be indexed to the Company’s stock and are classified as equity. Warrants with a strike price denominated in a currency other than the Company’s functional currency are considered not to be indexed to the Company’s stock and are classified as a liability. Warrants classified as equity are initially measured at fair value. Subsequent changes in fair value are not recognized as long as the warrants continue to be classified as equity. Warrants classified as a liability are initially measured at fair value with changes in fair value recorded in profit or loss in each reporting period. Production Costs Production costs consist of patent and license agreement amortization, production consulting fees, equipment depreciation, design and production costs, materials and supplies and patenting costs. Advertising Costs The Company charges all advertising and marketing costs to expense in the period incurred. Income Taxes Deferred income tax is accounted for using the asset and liability method. Deferred income taxes are provided for temporary differences in recognizing certain income and expense items for financial reporting purposes and tax reporting purposes. Such deferred income taxes primarily relate to the difference between the tax bases of assets and liabilities and their financial reporting amounts. Deferred tax assets and liabilities are measured by applying enacted statutory tax rates applicable to the future years in which deferred tax assets or liabilities are expected to be settled or realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. At this time, the Company is not able to project future taxable income over the periods in which the deferred tax assets are deductible and, accordingly, management is not able to determine if it is more likely than not that the Company will realize the benefits of these deductible differences. Fair Value of Financial Instruments Carrying values of cash, accounts payable and accrued liabilities, advances from related parties/shareholders, license assignment fee payable and stock subscribed approximate fair value because of the short-term nature of these items. Amounts receivable consists primarily of Harmonized Sales Tax (“HST”) receivable from the Government of Canada. HST is not a financial instrument. Foreign Currency The functional currency of the Company and its subsidiaries is the Canadian dollar. The accompanying consolidated financial statements are presented in Canadian dollars. Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in the loss in the period in which they arise.

Loss Per Share

Loss Per Share	12 Months Ended
	Aug. 31, 2018
Earnings Per Share [Abstract]
Loss Per Share	5. Loss Per Share The following table sets forth the computation of loss per share: For the Years Ended August 31, 2018 2017 2016 Net loss per share: Net loss $ (810,825 ) $ (5,071,687 ) $ (1,030,293 ) Weighted-average shares outstanding: Common stock 57,532,843 56,892,843 56,132,073 Number of shares used in per share computations 57,520,185 56,606,971 16,924,423 Loss per share $ (0.01 ) $ (0.09 ) $ (0.06 )

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Aug. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3 – Unobservable inputs that are supported by little or no market activity, which require management judgment or estimation. The Company measures its financial instruments at fair value. The carrying value of cash deposits is a reasonable estimate of its fair value due to the short maturity of the financial instrument. The Company’s stock purchase warrants are measured at fair value on a recurring basis.

Equipment, Net

Equipment, Net	12 Months Ended
	Aug. 31, 2018
Property, Plant and Equipment [Abstract]
Equipment, Net	7. Equipment, Net Equipment, at cost, consisted of: August 31, 2018 August 31, 2017 Mould equipment $ 155,300 $ 155,300 Website 28,875 28,875 Equipment at cost 184,175 184,175 Accumulated depreciation (155,107 ) (149,978 ) Loss on disposal of equipment (29,068 ) — Equipment, net $ — $ 34,197 Depreciation was $5,129 and $8,550 for the years ended August 31, 2018 and 2017, respectively.

Patents, Net

Patents, Net	12 Months Ended
	Aug. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Patents, Net	8. Patents, Net The following tables provide information regarding the patents: August 31, 2018 Gross carrying amount Accumulated amortization Writedowns Net carrying amount United States Patent $ 6,342,279 $ 2,984,602 $ 3,357,676 $ 1 Australian Patent 4,976 1,145 3,830 1 Canadian Patent 17,406 2,024 15,381 1 Chinese Patent 5,806 1,330 4,475 1 Patents abandoned 6,793 — 6,793 — $ 6,377,260 $ 2,989,101 $ 3,388,155 $ 4 August 31, 2017 Gross carrying amount Accumulated amortization Writedowns Net carrying amount United States Patent $ 6,342,279 $ 2,984,602 $ 3,357,676 $ 1 Australian Patent 4,976 1,145 3,830 1 Canadian Patent 17,406 2,024 15,381 1 Chinese Patent 5,806 1,330 4,475 1 Patents abandoned 6,793 — 6,793 — $ 6,377,260 $ 2,989,101 $ 3,388,155 $ 4 Also see Note 1. During the year ended August 31, 2017, management identified the following indicators of impairment indicating that the patents’ carrying amounts might not be recoverable: ● The inability to raise sufficient equity financing to implement its strategic plan; and ● Operating and cash flow losses since the Company completed the development of the US, Australian, Canadian and Chinese patents. During fiscal 2017, management was in the process of changing its focus in respect of the marketing and sale of tanning units and associated products. Management’s intention was to license commercial tanning units for use in stores and spas in the United States, to sell personal tanning units internationally and to supply the spray tan solution for those units. Ultimately, management was not in a position to be able to estimate the future cash flows attributable to the patents with any degree of certainty. Accordingly, the patents were written down to a nominal amount of $4 at August 31, 2017. In connection with the writedown of the patents, the fact that there had been minimal sales and no comparable products on the market to use as a point of reference, management was not able to determine whether inventory was stated at the lower of cost or market. Accordingly, inventory was written down to a nominal amount of $1 at August 31, 2017. During the year ended August 31, 2018, the Company discontinued its pursuit of the marketing and sale of the tanning units and associated products. Accordingly, inventory was written off at August 31, 2018.

License Agreement, Net

License Agreement, Net	12 Months Ended
	Aug. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
License Agreement, Net	9. License Agreement, Net August 31, 2018 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 374,932 $ 1,124,799 August 31, 2017 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 187,466 $ 1,312,265 As of August 31, 2018, amortization expense on the License Agreement for the next six years was expected to be as follows: Amount Year ending: 2019 $ 187,466 2020 187,466 2021 187,466 2022 187,466 2023 187,466 2024 187,469 Total $ 1,124,799 The Company has transitioned away from the manufacturing and marketing of Home Mist Tanning units to the designing, developing and marketing of technology for the treatment of neuromuscular defects, named Notox. The Company is currently in the design and prototype development stages and its objective is the completion of clinical testing trials for the purpose of obtaining Food and Drug Administration (“FDA”) 510(k) approval. Pursuant to the License Agreement, the Company is required to submit regulatory filings by November 30, 2019. During the current year, the Company was focused on in-depth market research for the purpose of understanding the global market for its technology, designing its brand and internal and external communications protocol to effectively communicate its vision to strategic partners, clinics and patients. The Company has prepared a five-year proforma projection of the undiscounted future cash flows attributable to the License Agreement, with the first year commencing upon completion of the design and receiving the FDA 510(k) approval. The Company’s CEO and President have committed to providing financing if and when necessary to fund the operating expenses until September 30, 2019. Also see Notes 1, 3 and 4.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Aug. 31, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	10. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of: August 31, 2018 August 31, 2017 Trade payables $ 1,412,277 $ 929,855 Vendor accruals 170,414 145,746 Accounts payable and accrued liabilities $ 1,582,691 $ 1,075,601

Related Party Transactions

Related Party Transactions	12 Months Ended
	Aug. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions The following amounts were payable to the Company’s related parties: ● At August 31, 2018, the Company owed $232,000 in advances payable to the President of the Company (2017 - $232,000). These advances are unsecured and bear interest at 3% per annum. Of this amount, $219,500 is due on demand and $12,500 has no repayment terms. Accrued interest payable to the President totaled $32,538 at August 31, 2018 (2017 - $25,578). ● At August 31, 2018, the Company owed $51,000 (2017 - $nil) in advances payable to the CEO of the Company. This balance bears no interest and has no repayment terms. ● At August 31, 2018, the Company owed $15,737 (2017 - $5,329) to the President of the Company for reimbursable expenses incurred on the Company’s behalf. ● At August 31, 2018, the Company owed $438,935 ($181,070 and US$197,522) (2017 - $271,984 ($181,070 and US$72,522)) in consulting fees to a company controlled by the President of the Company. ● At August 31, 2018, the Company owed $245,564 (US$188,100) (2017 - $79,102 (US$63,100)) in consulting fees to a company controlled by the CEO of the Company. ● At August 31, 2018, the Company owed $330,688 ($181,070 and US$114,606) (2017 - $259,448 ($181,070 and US$62,522)) in consulting fees to a company controlled by a major shareholder of the Company. ● At August 31, 2018, the Company owed $nil (2017 - $nil) in shareholder advances and $nil (2017 - $761) in accrued interest on these advances to the same major shareholder. ● At August 31, 2018, the Company owed $75,000 (2017 - $75,000) in consulting fees to a company controlled by the Company’s former CFO. During the year ended August 31, 2018, the Company had the following transactions with related parties: ● The President of the Company advanced $nil during the year ended August 31, 2018 (2017 - $nil). Interest expense of $6,960 was accrued on advances payable to the President of the Company during the year ended August 31, 2018 (2017 - $7,000). ● The CEO of the Company advanced $51,000 during the year ended August 31, 2018 (2017 - $nil). These advances are unsecured, bear no interest and have no repayment terms. ● Consulting fees paid or accrued as payable to a company controlled by the President of the Company were $159,674 (US$125,000), $163,466 (US$125,000) and $136,665 ($102,870 and US$26,040) for the years ended August 31, 2018, 2017 and 2016, respectively. ● Consulting fees paid or accrued as payable to a company controlled by the CEO of the Company were $159,674 (US$125,000), $163,466 (US$125,000) and $67,509 (US$56,040) for the years ended August 31, 2018, 2017 and 2016, respectively. ● Consulting fees paid or accrued as payable to a company controlled by a major shareholder of the Company were $65,481 (US$52,083), $163,466 (US$125,000) and $136,665 ($102,870 and US$26,040) for the years ended August 31, 2018, 2017 and 2016, respectively. All transactions with related parties occurred in the normal course of business and were measured at the exchange amount, which was the amount of consideration agreed upon between management and the related parties. Also see Notes 3, 12, 13 and 14.

Advances from Shareholders

Advances from Shareholders	12 Months Ended
	Aug. 31, 2018
Related Party Transactions [Abstract]
Advances from Shareholders	12. Advances from Shareholders Advances payable to shareholders totaled $145,000 at August 31, 2018 (2017 - $145,000). These advances are unsecured and bear interest at 3% per annum. There are no repayment terms. Interest expense of $3,589 was accrued on these advances during the year ended August 31, 2018 (2017 - $4,351). Accrued interest payable to shareholders totaled $16,971 at August 31, 2018 (2017 - $13,382).

License Assignment Fee Payable

License Assignment Fee Payable	12 Months Ended
	Aug. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
License Assignment Fee Payable	13. License Assignment Fee Payable Pursuant to the amendment to the Share Exchange Agreement, the Company agreed to pay an aggregate of US$1,000,000 to ZKC in the form of a one-time assignment fee. The assignment fee is payable in monthly instalments of US$50,000 beginning on October 1, 2016. Upon completion of any equity financing pursuant to which the Company raises gross proceeds of at least US$1,000,000, the outstanding balance is to be repaid in full. Since September 1, 2017, interest of 24% per annum, compounding annually, has been accrued on the outstanding balance payable. Interest expense of US$130,800 ($167,123) was accrued on the balance payable during the year ended August 31, 2018 (2017 - $nil). At August 31, 2018, the balance of the license assignment fee payable and interest payable to ZKC was US$675,800 ($882,257) (August 31, 2017 - US$545,000 ($683,212)). See Note 3.

Commitments

Commitments	12 Months Ended
	Aug. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments	14. Commitments On November 16, 2015, the Company entered into a consulting agreement (the “ECC Agreement”) with Edgewater Consulting Corp., a private Ontario corporation (“ECC”). Pursuant to the ECC Agreement, ECC, through its principal, acted in the capacity of CFO of the Company. The ECC Agreement was terminated effective November 10, 2016. A signing bonus of 750,000 exchangeable preferred shares of Subco was issued on August 24, 2016. As at August 31, 2018, ECC is entitled to $75,000 (August 31, 2017 - $75,000) in accrued remuneration. On December 1, 2015, the Company entered into consulting agreements with 1040614 Ontario Ltd., a private Ontario corporation (the “Old 1040614 Agreement”), and MCM Consulting, an Ontario sole proprietorship (the “Old MCM Agreement”, and together with the Old 1040614 Agreement, the “Old Agreements”). Pursuant to the Old 1040614 Agreement, the company, through its principal, performed various services related to business development, strategic planning and capital-raising for the Company. Pursuant to the Old MCM Agreement, the sole proprietor acted in the capacity of CEO of the Company. On June 13, 2016, the Old 1040614 and MCM Agreements were terminated and replaced by the 1040614 and MCM Agreements (see below). As at August 31, 2018, 1040614 and MCM are each entitled to $80,770 (August 31, 2017 - $80,770) in accrued remuneration in respect of the Old Agreements. On February 4, 2016, the Company entered into a consulting agreement (the “Old ZKC Agreement”) with Zoran K Corporation, a private Ontario corporation (“ZKC”). Pursuant to the Old ZKC Agreement, ZKC, through its principal, acted in the capacity of the Company’s exclusive sales, marketing and product development agent. On June 13, 2016, the Old ZKC Agreement was terminated and replaced by the ZKC Agreement (see below). As at August 31, 2018, there is no remuneration payable (August 31, 2017 - $nil) by the Company under the Old ZKC Agreement. On June 13, 2016, the Company entered into consulting agreements with 1040614 Ontario Ltd. (the “1040614 Agreement”), MCM Consulting (the “MCM Agreement”) and ZKC (the “ZKC Agreement”). Pursuant to the 1040614 Agreement, the company, through its principal, performs general consulting services on behalf of the Company. Pursuant to the MCM Agreement, the sole proprietor acts in the capacity of President of the Company. Pursuant to the ZKC Agreement, ZKC, through its principal, acts in the capacity of CEO of the Company. Each consulting agreement is for a period of 10 years, with successive automatic renewal periods of two years until terminated. Pursuant to these consulting agreements, each consultant is entitled to receive the following compensation: ● Remuneration – an aggregate of US$125,000 per annum plus HST on a bi-monthly basis; ● EPS Bonus – when the Company generates earnings per share of $0.05, plus any multiple thereof, the Company shall issue the consultant 1,000,000 shares of the Company’s common stock and pay the consultant US$250,000 plus HST; ● Change of Control Bonus – immediately prior to the completion of a change of control (as defined in these consulting agreements) the Company shall issue the consultant an aggregate of 20,000,000 shares of the Company’s common stock; and ● Additional Bonus – the company may from time to time pay the consultant one or more bonuses as determined by the Board of Directors at its sole discretion. Effective February 3, 2018, the Company terminated the 1040614 Agreement. On August 31, 2018, the Company renewed its premises lease for another year beginning on September 1, 2018 for a rental of $21,000 for the year plus HST.

Stockholders' Deficiency

Stockholders' Deficiency	12 Months Ended
	Aug. 31, 2018
Equity [Abstract]
Stockholders' Deficiency	15. Stockholders’ Deficiency As at August 31, 2018, the Company was authorized to issue 300,000,000 (August 31, 2017 - 300,000,000) shares of common stock at a par value of $US0.001. See Note 20. On August 25, 2016, the Company completed a reverse split of the Company’s common stock at the ratio of one new share for every two existing shares. All share and per share amounts have been adjusted to reflect this reverse split. At August 31, 2018, the Company had 57,532,843 shares of common stock legally issued and outstanding (2017 - 56,892,843 shares). On June 28, 2013, pursuant to the Exchange Agreement, the Company acquired 39,015,439 common shares of TSI in exchange for the issuance of 39,015,439 preferred shares of Subco to the Selling Shareholders on a one-for-one basis. As a result of the Exchange Agreement, TSI became the Company’s majority-owned subsidiary. Each preferred share of Subco is exchangeable into one share of the Company’s common stock at the option of the holder subject to certain restrictions. As at August 31, 2018 and 2017, none of the preferred shares had been exchanged. As a condition of the closing of the Exchange Agreement, the Company also entered into a Support Agreement and a Voting and Exchange Trust Agreement on the Closing Date. The Support Agreement ensures that the obligations of Subco remain effective until all of the preferred shares have been exchanged. The Voting and Exchange Trust Agreement provides and establishes a procedure whereby the voting rights attached to shares of the Company’s common stock are exercisable by the registered holders of the preferred shares of Subco. The Trustee (as defined in the Voting and Exchange Trust Agreement) holds legal title to a Special Voting Share to which voting rights are attached for the benefit of those shareholders. The Trustee holds the Special Voting Share solely for the use and benefit of the those shareholders. Common Stock Issuances During the year ended August 31, 2018, the Company completed the following common stock transactions: ● On September 21, 2017, the Company closed a US dollar financing pursuant to which the Company issued 630,000 units at US$1.00 per unit for gross proceeds of $830,674 (US$630,000), with each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of common stock exercisable at a price of US$1.40 per share until September 7, 2019. $491,041 was allocated to common stock and $339,633 was allocated to stock purchase warrants. The Company paid cash finder’s fees of $6,435 (US$5,000) and issued 5,000 finder’s stock purchase warrants exercisable at US$1.40 per warrant share until July 17, 2019, valued at $2,581 and credited to stock purchase warrants. ● On September 21, 2017, the Company issued 10,000 shares of common stock at $0.80 per share for gross proceeds of $8,000 pursuant to the exercise of warrants during the year ended August 31, 2017. $2,049 of the gross proceeds received that was allocated to these warrants has been deducted from additional paid-in capital. At August 31, 2017, the gross proceeds received of $838,674 for the financings that closed September 7, 2017 and September 21, 2017 were reported as stock subscribed. During the year ended August 31, 2017, the Company completed the following common stock transactions: ● On October 31, 2016, the Company closed a concurrent Canadian and US dollar financing as follows: o Canadian financing – the Company issued 140,000 units at $0.50 per unit for gross proceeds of $70,000, with each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of common stock exercisable at a price of $0.80 per share until October 31, 2018. $41,314 was allocated to common stock and $28,686 was allocated to additional paid-in capital. US financing – the Company issued 220,770 units at US$0.50 per unit for gross proceeds of $146,716 (US$110,385), with each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of common stock exercisable at a price of US$0.80 per share until October 31, 2018. $86,027 was allocated to common stock and $60,689 was allocated to stock purchase warrants. ● On November 2, 2016, the Company closed a US dollar financing pursuant to which the Company issued 400,000 units at US$1.00 per unit for gross proceeds of $524,230 (US$400,000), with each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of common stock exercisable at a price of US$1.40 per share until November 2, 2018. $286,950 was allocated to common stock and $237,280 was allocated to stock purchase warrants. The Company paid cash finder’s fees of $19,899 and issued 15,000 finder’s stock purchase warrants exercisable at US$1.40 per warrant share until September 28, 2018, valued at $8,742 and credited to stock purchase warrants. Stock Subscribed During the year ended August 31, 2018, $10,000 in stock subscriptions was received pursuant to the exercise of 12,500 warrants at a price of $0.80 per share in February 2018. This stock remained subscribed for as at August 31, 2018. During the year ended August 31, 2017, $838,674 ($8,000 and US$630,000) in stock subscriptions was received pursuant to individual private placements. These subscriptions were for a total of: ● 10,000 shares of common stock of the Company at a price of $0.80 per share pursuant to the exercise of stock purchase warrants. These shares were issued on September 21, 2017. ● 630,000 units of the Company at a price of US$1.00 per unit. Each unit consists of one share of the Company’s common stock and one warrant to purchase one share of common stock exercisable at a price of US$1.40 per share for a period of 24 months from the closing date of the financing. These units were issued on September 7, 2017. Stock Purchase Warrants The continuity of Canadian dollar denominated stock purchase warrants for the year ended August 31, 2018 is as follows: Expiry Date Price August 31, 2017 Issued Exercised August 31, 2018 October 31, 2018 $ 0.80 130,000 — (12,500 ) 117,500 At August 31, 2018, the weighted-average remaining contractual life of Canadian dollar warrants outstanding was 0.17 years (August 31, 2017 - 1.17). The continuity of US dollar denominated stock purchase warrants for the year ended August 31, 2018 is as follows: Expiry Date Price August 31, 2017 Issued Exercised August 31, 2018 September 30, 2018 – Finder US$1.40 15,000 — — 15,000 October 31, 2018 US$0.80 220,770 — — 220,770 November 2, 2018 US$1.40 400,000 — — 400,000 July 17, 2019 – Finder US$1.40 — 5,000 — 5,000 September 7, 2019 US$1.40 — 630,000 — 630,000 635,770 635,000 — 1,270,770 At August 31, 2018, the weighted-average remaining contractual life of US dollar warrants outstanding was 0.59 years (August 31, 2017 - 1.17 years). The Company used the Black-Scholes Option Pricing Model to determine the fair values of unit warrants and finder’s warrants issued pursuant to private placements during the years ended August 31, 2018 and 2017 with the following assumptions: August 31, 2018 August 31, 2017 Expected dividend yield 0.00 % 0.00 % Risk-free interest rate 1.47% - 2.04 % 0.54% - 0.55 % Expected stock price volatility 100.00 % 100.00 % Expected life of warrants 0.08 – 2 years 2 years See Notes 4 and 20.

Taxes

Taxes	12 Months Ended
	Aug. 31, 2018
Income Tax Disclosure [Abstract]
Taxes	16. Taxes Income tax expense differs from the amounts computed by applying the statutory income tax rate to net loss before income taxes as follows: Year Ended August 31, 2018 2017 2016 Net loss before income taxes $ (810,825 ) $ (5,071,687 ) $ (1,030,293 ) Tax rate (1 ) (2 ) (2 ) Calculated income tax recovery (199,277 ) (1,391,061 ) (273,260 ) Adjustment for deductible and non-deductible amounts (77,794 ) 1,130,327 48,858 Unrecognized benefit of non-capital losses 277,071 260,734 224,402 Income tax recovery $ — $ — $ — (1) Canada – 26.50%; United States – 21% (2) Canada – 26.50%; United States – 34% Deferred Taxes Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Significant components of the Company’s deferred tax assets are as follows: August 31, 2018 August 31, 2017 Deferred tax assets: Net operating loss carryforwards $ 2,029,000 $ 1,784,000 Temporary deductible differences (net) 753,000 834,000 2,782,000 2,618,000 Valuation allowance (2,782,000 ) (2,618,000 ) Net deferred tax assets $ — $ — Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. A valuation allowance was established based upon management’s inability to determine whether sufficient future profits will be generated. The Company has approximately $7,844,000 of United States and Canadian net operating loss and non-capital loss carryforwards expiring from 2024 to 2038 .

Risks and Uncertainties

Risks and Uncertainties	12 Months Ended
	Aug. 31, 2018
Risks and Uncertainties [Abstract]
Risks and Uncertainties	17. Risks and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect its future operating results and cause actual results to vary materially from expectations include, but are not limited to: current economic conditions; the Company’s degree of success in securing regulatory approval and marketing products developed pursuant to the License Agreement; increasing competition; and dependence on its existing management and key personnel.

Accounting Pronouncements

Accounting Pronouncements	12 Months Ended
	Aug. 31, 2018
Accounting Changes and Error Corrections [Abstract]
Accounting Pronouncements	18. Accounting Pronouncements The Financial Accounting Standards Board (“FASB”) issued the following Accounting Standard Updates (“ASUs”) that may be of relevance to the Company. The Company is currently assessing the impact that the adoption of these ASUs will have on its financial statements and related disclosures. ● February 2017 – ASU No. 2017-05, “Other Income – Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20)” clarifies the scope of asset derecognition guidance and accounting for the partial sale of non-financial assets, as well as provides guidance for recognizing gains and losses from the transfer of non-financial assets in contracts with non-customers. The amendments in this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company expects the impact of adoption of this ASU to be minimal. ● September 2017 – ASU No. 2017-13, “Leases (Topic 842)” provides the requirements of financial accounting and reporting for lessees and lessors and establishes principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease under Accounting Standards Codification 842, Leases

Contingent Liability

Contingent Liability	12 Months Ended
	Aug. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingent Liability	19. Contingent Liability Pursuant to the Exchange Agreement, as amended, the Company may be required to acquire up to 296,500 common shares of TSI, being those TSI shares still outstanding, in exchange for 148,250 preferred shares of Subco on a one-for-two basis. Such preferred shares would then be exchangeable on the same basis as the approximately 50 million Subco preferred shares currently outstanding (see Notes 2 and 15). On August 24, 2016, 21,672,623 common shares of TSI were exchanged for 10,836,312 preferred shares of Subco.

Subsequent Events

Subsequent Events	12 Months Ended
	Aug. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events The following warrants expired unexercised subsequent to year end: ● 15,000 finder warrants to purchase one share of common stock exercisable at a price of US$1.40 per share expired unexercised September 30, 2018; ● 220,770 warrants to purchase one share of common stock exercisable at a price of US$0.80 per share and 117,500 warrants to purchase one share of common stock exercisable at a price of $0.80 per share expired unexercised October 31, 2018; and ● 400,000 warrants to purchase one share of common stock exercisable at a price of US$1.40 per share expired unexercised November 2, 2018. The Company’s CEO advanced $20,000 to the Company in September 2018 and a further $5,000 to the Company in October 2018. These advances bear no interest and have no repayment terms. On October 9, 2018, the Company’s shareholders and directors approved a change of the Company’s name from Tropic International Inc. to Notox Technologies Corp. and an increase in the Company’s authorized capital from 300,000,000 shares of common stock to 500,000,000 shares of common stock . The name change and authorized capital increase were effected on November 19, 2018.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the financial statements of the Company, TSI, Notox, Subco and 1894631 Ontario Inc., the Company’s subsidiaries. All significant inter-company balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to equipment, fair values of intangible assets, useful lives of intangible assets and the likelihood of realization of its deferred tax assets .
Concentration of Risk	Concentration of Risk The financial instrument which potentially subjects the Company to a concentration of credit risk is cash. The Company places its cash in an account with a high credit quality financial institution.
Significant Accounting Policies	Significant Accounting Policies The accompanying consolidated financial statements reflect the application of certain significant accounting policies. There have been no material changes to the Company’s significant accounting policies that are disclosed in the consolidated financial statements and notes thereto during the period ended August 31, 2018.
Inventory	Inventory Inventory is stated at the lower of cost, computed using the first-in, first-out method, or market. If the cost of inventory exceeds its market value, a provision is made currently for the difference between the cost and market value.
Equipment, Net	Equipment, Net Equipment is stated at cost, net of accumulated depreciation. Equipment is depreciated over the estimated useful life of the asset. Mould equipment is depreciated at 20% on a declining-balance basis. The website was depreciated on a straight-line basis over five years. One-half of these rates are used in the year of acquisition. Replacements and major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Upon retirement or sale, the cost of assets disposed of and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is credited or charged to operations.
Intangible Assets	Intangible Assets Patents The US Patent is recorded at the value attributed to the shares issued by TSI in connection with its acquisition less accumulated amortization and impairment writedowns. The US Patent was issued on September 29, 2009 and is effective until September 29, 2026. The Australian, Canadian and Chinese Patents are recorded at the application costs incurred less accumulated amortization and impairment writedowns. The Australian Patent was issued on October 16, 2014 and is effective until April 5, 2027. The Canadian Patent was issued on June 21, 2016 and is effective until April 5, 2027. The Chinese Patent was issued on December 28, 2016 and is effective until February 1, 2033. Upon expiration, the patents can be extended subject to certain changes required to secure the extension. Although the effects of obsolescence, demand, competition and other economic factors (such as stability of the industry, technological advances and legislative action that results in an uncertain or changing regulatory environment) can have an adverse effect on the industry and saleability of patented products, management is not currently aware of any known adverse factors that will affect the patents in the future. Costs incurred for patents which are in the process of being completed will be amortized over the life of the patent when the patent is issued. At the time that the patents were issued, the Company did not believe that there were any limits to how long the Home Mist Tanning units could sell in the market place. Accordingly, management had determined that the best estimates of useful lives of the US, Australian, Canadian and Chinese Patents were 17, 13, 11 and 16 years, respectively. At this time, the Company does not believe that the patents will have a residual value at the end of their useful lives. License Agreement The License Agreement is recorded at estimated fair value plus acquisition costs less accumulated amortization and impairment writedowns. The term of the License Agreement continues until the expiration of the last to expire of the Licensed Patents (as defined in the License Agreement). All costs related to the development of the licensed technology are expensed as incurred. The technology licensed by Notox is a platform that provides the Company access to four large market segments or verticals (derma, pain, body and headache) that include the fields of aesthetics, drug-free pain management, body contouring and perspiration control. Based on management’s experience, it takes approximately two years to fully develop each vertical, with each vertical being developed in sequence. Accordingly, management’s best estimate of the amortization period for the License Agreement is eight years. Amortization and Impairment Definite-lived intangible assets are required to be amortized using a method that reflects the pattern in which the economic benefits of the intangible assets are consumed or utilized. Management was not able to determine with any amount of certainty the number of Home Mist Tanning units that would be sold over the useful lives of the patents. Accordingly, the patents were being amortized on a straight-line basis over the period of their useful lives. The License Agreement is being amortized over eight years based on management’s best estimate of the time required to develop the four verticals as explained above. Intangible assets subject to amortization are required to be reviewed for impairment. An impairment loss must be recognized if the intangible asset’s carrying amount is not recoverable and the carrying amount exceeds fair value. The Company applies the following three-step process to identify, recognize and measure impairment of intangible assets: ● Consider whether indicators of impairment are present indicating that the intangible assets’ carrying amount might not be recoverable; ● If indicators are present, perform a recoverability test by comparing the sum of the estimated undiscounted future cash flows attributable to the intangible assets to their carrying amounts; and ● If the undiscounted cash flows used in the recoverability test are less than the intangible assets’ carrying amount, determine the intangible assets’ fair value and recognize an impairment loss if the carrying amount exceeds fair value. Because of the unique nature of a patent and a license agreement, income-producing definite-lived intangible assets, the calculation of cash flows can be very difficult to estimate. In this case, the estimated cash flows reflect the direct revenue expected to be generated by the License Agreement as well as an allocation of expenses.
Leases	Leases The Company currently rents premises pursuant to an operating lease.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets Long-lived assets, including equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount should be evaluated. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds its fair value.
Stock Purchase Warrants	Stock Purchase Warrants When the Company undertakes a private placement, it may issue units comprised of common stock of the Company and warrants to acquire common stock of the Company. Warrants with a strike price denominated in the Company’s functional currency (the Canadian dollar) are considered to be indexed to the Company’s stock and are classified as equity. Warrants with a strike price denominated in a currency other than the Company’s functional currency are considered not to be indexed to the Company’s stock and are classified as a liability. Warrants classified as equity are initially measured at fair value. Subsequent changes in fair value are not recognized as long as the warrants continue to be classified as equity. Warrants classified as a liability are initially measured at fair value with changes in fair value recorded in profit or loss in each reporting period.
Production Costs	Production Costs Production costs consist of patent and license agreement amortization, production consulting fees, equipment depreciation, design and production costs, materials and supplies and patenting costs.
Advertising Costs	Advertising Costs The Company charges all advertising and marketing costs to expense in the period incurred.
Income Taxes	Income Taxes Deferred income tax is accounted for using the asset and liability method. Deferred income taxes are provided for temporary differences in recognizing certain income and expense items for financial reporting purposes and tax reporting purposes. Such deferred income taxes primarily relate to the difference between the tax bases of assets and liabilities and their financial reporting amounts. Deferred tax assets and liabilities are measured by applying enacted statutory tax rates applicable to the future years in which deferred tax assets or liabilities are expected to be settled or realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. At this time, the Company is not able to project future taxable income over the periods in which the deferred tax assets are deductible and, accordingly, management is not able to determine if it is more likely than not that the Company will realize the benefits of these deductible differences.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Carrying values of cash, accounts payable and accrued liabilities, advances from related parties/shareholders, license assignment fee payable and stock subscribed approximate fair value because of the short-term nature of these items. Amounts receivable consists primarily of Harmonized Sales Tax (“HST”) receivable from the Government of Canada. HST is not a financial instrument.
Foreign Currency	Foreign Currency The functional currency of the Company and its subsidiaries is the Canadian dollar. The accompanying consolidated financial statements are presented in Canadian dollars. Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in the loss in the period in which they arise.

Reverse Takeover (Tables)

Reverse Takeover (Tables)	12 Months Ended
	Aug. 31, 2018
Business Combinations [Abstract]
Schedule of Fair Values of Assets Acquired and Liabilities Assumed	The fair values of assets acquired and liabilities assumed were as follows: Cash $ 1,774 Subscriptions receivable 10 Accounts payable and accrued liabilities (32,488 ) Loan payable to TSI (25,454 ) Net liabilities acquired $ (56,158 )

Asset Acquisition and License_2

Asset Acquisition and License Agreement (Tables)	12 Months Ended
	Aug. 31, 2018
Business Combinations [Abstract]
Schedule of Fair Value and Carrying Value of License Agreement	The fair value and gross carrying value of the License Agreement is as follows: License Agreement $ 133,212 Cash 131 Accrued liabilities (5,423 ) Capital stock exchanged (50,000,000 shares at US$0.002 per share) $ 127,920 Fair value of License Agreement $ 133,212 Acquisition costs 19,519 Assignment fee (US$1,000,000) 1,347,000 Gross carrying value of License Agreement $ 1,499,731

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Aug. 31, 2018
Earnings Per Share [Abstract]
Schedule of Computation of Loss Per Share	The following table sets forth the computation of loss per share: For the Years Ended August 31, 2018 2017 2016 Net loss per share: Net loss $ (810,825 ) $ (5,071,687 ) $ (1,030,293 ) Weighted-average shares outstanding: Common stock 57,532,843 56,892,843 56,132,073 Number of shares used in per share computations 57,520,185 56,606,971 16,924,423 Loss per share $ (0.01 ) $ (0.09 ) $ (0.06 )

Equipment, Net (Tables)

Equipment, Net (Tables)	12 Months Ended
	Aug. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Equipment Net	Equipment, at cost, consisted of: August 31, 2018 August 31, 2017 Mould equipment $ 155,300 $ 155,300 Website 28,875 28,875 Equipment at cost 184,175 184,175 Accumulated depreciation (155,107 ) (149,978 ) Loss on disposal of equipment (29,068 ) — Equipment, net $ — $ 34,197

Patents, Net (Tables)

Patents, Net (Tables)	12 Months Ended
	Aug. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	The following tables provide information regarding the patents: August 31, 2018 Gross carrying amount Accumulated amortization Writedowns Net carrying amount United States Patent $ 6,342,279 $ 2,984,602 $ 3,357,676 $ 1 Australian Patent 4,976 1,145 3,830 1 Canadian Patent 17,406 2,024 15,381 1 Chinese Patent 5,806 1,330 4,475 1 Patents abandoned 6,793 — 6,793 — $ 6,377,260 $ 2,989,101 $ 3,388,155 $ 4 August 31, 2017 Gross carrying amount Accumulated amortization Writedowns Net carrying amount United States Patent $ 6,342,279 $ 2,984,602 $ 3,357,676 $ 1 Australian Patent 4,976 1,145 3,830 1 Canadian Patent 17,406 2,024 15,381 1 Chinese Patent 5,806 1,330 4,475 1 Patents abandoned 6,793 — 6,793 — $ 6,377,260 $ 2,989,101 $ 3,388,155 $ 4

License Agreement, Net (Tables)

License Agreement, Net (Tables)	12 Months Ended
	Aug. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of License Agreement	August 31, 2018 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 374,932 $ 1,124,799 August 31, 2017 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 187,466 $ 1,312,265
Schedule of Amortization Expense on Intangible Assets	As of August 31, 2018, amortization expense on the License Agreement for the next six years was expected to be as follows: Amount Year ending: 2019 $ 187,466 2020 187,466 2021 187,466 2022 187,466 2023 187,466 2024 187,469 Total $ 1,124,799

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Aug. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accounts payable and accrued liabilities consisted of: August 31, 2018 August 31, 2017 Trade payables $ 1,412,277 $ 929,855 Vendor accruals 170,414 145,746 Accounts payable and accrued liabilities $ 1,582,691 $ 1,075,601

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	12 Months Ended
	Aug. 31, 2018
Equity [Abstract]
Schedule of Stock Purchase Warrants	The continuity of Canadian dollar denominated stock purchase warrants for the year ended August 31, 2018 is as follows: Expiry Date Price August 31, 2017 Issued Exercised August 31, 2018 October 31, 2018 $ 0.80 130,000 — (12,500 ) 117,500 At August 31, 2018, the weighted-average remaining contractual life of Canadian dollar warrants outstanding was 0.17 years (August 31, 2017 - 1.17). The continuity of US dollar denominated stock purchase warrants for the year ended August 31, 2018 is as follows: Expiry Date Price August 31, 2017 Issued Exercised August 31, 2018 September 30, 2018 – Finder US$1.40 15,000 — — 15,000 October 31, 2018 US$0.80 220,770 — — 220,770 November 2, 2018 US$1.40 400,000 — — 400,000 July 17, 2019 – Finder US$1.40 — 5,000 — 5,000 September 7, 2019 US$1.40 — 630,000 — 630,000 635,770 635,000 — 1,270,770
Schedule of Stock Options Valuation Assumptions	The Company used the Black-Scholes Option Pricing Model to determine the fair values of unit warrants and finder’s warrants issued pursuant to private placements during the years ended August 31, 2018 and 2017 with the following assumptions: August 31, 2018 August 31, 2017 Expected dividend yield 0.00 % 0.00 % Risk-free interest rate 1.47% - 2.04 % 0.54% - 0.55 % Expected stock price volatility 100.00 % 100.00 % Expected life of warrants 0.08 – 2 years 2 years

Taxes (Tables)

Taxes (Tables)	12 Months Ended
	Aug. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Statutory Income Tax Rate	Income tax expense differs from the amounts computed by applying the statutory income tax rate to net loss before income taxes as follows: Year Ended August 31, 2018 2017 2016 Net loss before income taxes $ (810,825 ) $ (5,071,687 ) $ (1,030,293 ) Tax rate (1 ) (2 ) (2 ) Calculated income tax recovery (199,277 ) (1,391,061 ) (273,260 ) Adjustment for deductible and non-deductible amounts (77,794 ) 1,130,327 48,858 Unrecognized benefit of non-capital losses 277,071 260,734 224,402 Income tax recovery $ — $ — $ — (1) Canada – 26.50%; United States – 21% (2) Canada – 26.50%; United States – 34%
Schedule of Deferred Tax Assets	Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Significant components of the Company’s deferred tax assets are as follows: August 31, 2018 August 31, 2017 Deferred tax assets: Net operating loss carryforwards $ 2,029,000 $ 1,784,000 Temporary deductible differences (net) 753,000 834,000 2,782,000 2,618,000 Valuation allowance (2,782,000 ) (2,618,000 ) Net deferred tax assets $ — $ —

Company Overview and Basis of_2

Company Overview and Basis of Presentation (Details Narrative) - CAD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Dec. 28, 2016	Aug. 31, 2016	Jun. 21, 2016	Jun. 13, 2016	Aug. 31, 2015	Oct. 16, 2014	Mar. 11, 2013
Subscription received amount used for patent	$ 6,377,260	$ 6,377,260
Carrying value of patent, net		4
Deficit	(11,783,486)	(10,972,661)
Working capital deficiency	3,203,961	3,134,766
Stockholders' equity	2,306,865	1,986,065		$ (3,016,652)			$ (3,603,659)
Operating expenses	100,000
Accounts payable and accrued liabilities	1,582,691	1,075,601
Advances from related parties/shareholders	477,509	415,960
License assignment fee payable	882,257	683,212
Extent remaining payment balance cannot be deferred	335,000
Related Parties and Major Shareholders [Member]
Cash liabilities	2,942,000	2,175,000
Accounts payable and accrued liabilities	2,607,000
Advances from related parties/shareholders	1,248,000
License assignment fee payable	477,000
Payable to related parties and/or major shareholders	882,000
United States Patent [Member]
Subscription received amount used for patent	6,342,279	6,342,279							$ 6,342,279
Chinese Patent [Member]
Subscription received amount used for patent	$ 5,806	$ 5,806
Notox Bioscience Inc [Member]
Purpose of acquiring right percentage						100.00%
Tropic Spa Inc [Member] | Australian Patent [Member]
Application costs								$ 4,976
Tropic Spa Inc [Member] | Canadian Patent [Member]
Application costs					$ 17,406
Tropic Spa Inc [Member] | Chinese Patent [Member]
Application costs			$ 5,806

Reverse Takeover (Details Narra

Reverse Takeover (Details Narrative) - CAD ($)		Aug. 24, 2016	Jun. 28, 2013	Aug. 31, 2018	Aug. 31, 2016
Common Stock [Member]
Common shares acquired	[1]				50,000,000
Tropic Spa Inc [Member]
Percentage of redeemable outstanding preferred shares on a pro-rata basis			1.00%
Percentage of control of issued and outstanding of common stock			87.00%
Tropic Spa Inc [Member] | Minimum [Member]
Expected revenue, gross			$ 1,000,000
Tropic Spa Inc [Member] | Common Stock [Member]
Common shares acquired		21,672,623	39,015,439	296,500
Percentage of shares exchange for preferred stock of holding company			78.00%
Subco [Member] | Preferred Stock [Member]
Common shares acquired			39,015,439
Number of preferred stock for exchange		10,836,312	39,015,439	148,250
[1]	The above presentation reflects a 1:2 reverse split of the Company's common stock on August 25, 2016. See Note 16.

Reverse Takeover - Schedule of

Reverse Takeover - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details)	Aug. 31, 2018CAD ($)
Business Combinations [Abstract]
Cash	$ 1,774
Subscriptions receivable	10
Accounts payable and accrued liabilities	(32,488)
Loan payable to TSI	(25,454)
Net liabilities acquired	$ (56,158)

Asset Acquisition and License_3

Asset Acquisition and License Agreement (Details Narrative)	Jun. 13, 2016shares	Aug. 31, 2018CAD ($)	Aug. 31, 2018USD ($)	Aug. 31, 2017CAD ($)	Aug. 31, 2017USD ($)	Nov. 23, 2016USD ($)
License assignment fee payable		$ 882,257		$ 683,212
Accrued and unreimbursed patenting costs		227,707		197,765
USD Currency [Member]
Accrued and unreimbursed patenting costs			$ 174,421		$ 157,758
Notox Bioscience Inc [Member]
Purpose of acquiring right percentage	100.00%
Issuance of common stock shares for exchange | shares	50,000,000
Owned subsidiary description	As a result of the share exchange and on the Second Closing Date, the Notox Shareholders controlled approximately 89% of the issued and outstanding common stock of the Company (52.5% on a fully-exchanged basis) and Notox became a wholly-owned subsidiary of the Company.
Percentage of control of issued and outstanding of common stock	89.00%
Zoran Holding Corporation [Member]
Purpose of acquiring right percentage	100.00%
Zoran K Corporation [Member]
License assignment fee payable		$ 882,257		$ 683,212		$ 1,000,000
Zoran K Corporation [Member] | USD Currency [Member]
License assignment fee payable			$ 675,800		$ 545,000

Asset Acquisition and License_4

Asset Acquisition and License Agreement - Schedule of Fair Value and Carrying Value of License Agreement (Details) - License Agreement [Member]	Aug. 31, 2018CAD ($)
License Agreement	$ 133,212
Cash	131
Accrued liabilities	(5,423)
Capital stock exchanged (50,000,000 shares at US$0.002 per share)	127,920
Fair value of License Agreement	133,212
Acquisition costs	19,519
Assignment fee (US$1,000,000)	1,347,000
Gross carrying value of License Agreement	$ 1,499,731

Asset Acquisition and License_5

Asset Acquisition and License Agreement - Schedule of Fair Value and Carrying Value of License Agreement (Details) (Parenthetical)	12 Months Ended
	Aug. 31, 2018CAD ($)$ / sharesshares	Aug. 31, 2018USD ($)	Aug. 31, 2017CAD ($)
License assignment fee payable	$ 882,257		$ 683,212
License Agreement [Member]
Number of shares exchanged | shares	50,000,000
Exchanged share, per share value | $ / shares	$ 0.002
License assignment fee payable		$ 1,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative)	Dec. 28, 2016	Jun. 21, 2016	Oct. 16, 2014	Sep. 29, 2009	Aug. 31, 2018
Mould equipment, depreciation percentage					20.00%
Website, useful life					5 years
United States Patent [Member]
Patent expiration date				Sep. 29, 2026
Estimate of useful life of patent				17 years
Australian Patent [Member]
Patent expiration date			Apr. 5, 2027
Estimate of useful life of patent			13 years
Canadian Patent [Member]
Patent expiration date		Apr. 5, 2027
Estimate of useful life of patent		11 years
Chinese Patent [Member]
Patent expiration date	Feb. 1, 2033
Estimate of useful life of patent	16 years

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Computation of Loss Per Share (Details) - CAD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Aug. 31, 2016
Earnings Per Share [Abstract]
Net loss	$ (810,825)	$ (5,071,687)	$ (1,030,293)
Common stock	57,532,843	56,892,843	56,132,073
Number of shares used in per share computations	57,520,185	56,606,971	16,924,423
Loss per share	$ (0.01)	$ (0.09)	$ (0.06)

Equipment, Net (Details Narrati

Equipment, Net (Details Narrative) - CAD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Aug. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation	$ 5,129	$ 8,550	$ 10,687

Equipment, Net - Schedule of Eq

Equipment, Net - Schedule of Equipment Net (Details) - CAD ($)	Aug. 31, 2018	Aug. 31, 2017
Property, Plant and Equipment [Abstract]
Mould equipment	$ 155,300	$ 155,300
Website	28,875	28,875
Equipment at cost	184,175	184,175
Accumulated depreciation	(155,107)	(149,978)
Loss on disposal of equipment	(29,068)
Equipment, net		$ 34,197

Patents, Net (Details Narrative

Patents, Net (Details Narrative) - CAD ($)	Aug. 31, 2018	Aug. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents, nominal amount	$ 4	$ 4
Inventory, nominal amount		$ 1

Patents, Net - Schedule of Pate

Patents, Net - Schedule of Patents (Details) - CAD ($)	Aug. 31, 2018	Aug. 31, 2017	Mar. 11, 2013
Patent, Gross carrying amount	$ 6,377,260	$ 6,377,260
Patent, Accumulated amortization	2,989,101	2,989,101
Patent, Write-downs	3,388,155	3,388,155
Patent, Net carrying amount	4	4
United States Patent [Member]
Patent, Gross carrying amount	6,342,279	6,342,279	$ 6,342,279
Patent, Accumulated amortization	2,984,602	2,984,602
Patent, Write-downs	3,357,676	3,357,676
Patent, Net carrying amount	1	1
Australian Patent [Member]
Patent, Gross carrying amount	4,976	4,976
Patent, Accumulated amortization	1,145	1,145
Patent, Write-downs	3,830	3,830
Patent, Net carrying amount	1	1
Canadian Patent [Member]
Patent, Gross carrying amount	17,406	17,406
Patent, Accumulated amortization	2,024	2,024
Patent, Write-downs	15,381	15,381
Patent, Net carrying amount	1	1
Chinese Patent [Member]
Patent, Gross carrying amount	5,806	5,806
Patent, Accumulated amortization	1,330	1,330
Patent, Write-downs	4,475	4,475
Patent, Net carrying amount	1	1
Patents Abandoned [Member]
Patent, Gross carrying amount	6,793	6,793
Patent, Accumulated amortization
Patent, Write-downs	6,793	6,793
Patent, Net carrying amount

License Agreement, Net - Schedu

License Agreement, Net - Schedule of License Agreement (Details) - CAD ($)	Aug. 31, 2018	Aug. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
License Agreement, Gross carrying amount	$ 1,499,731	$ 1,499,731
License Agreement, Accumulated amortization	374,932	187,466
License Agreement, Net carrying amount	$ 1,124,799	$ 1,312,265

License Agreement, Net - Sche_2

License Agreement, Net - Schedule of Amortization Expense on Intangible Assets (Details) - CAD ($)	Aug. 31, 2018	Aug. 31, 2017
Total		$ 4
License Agreement [Member]
2,019	$ 187,466
2,020	187,466
2,021	187,466
2,022	187,466
2,023	187,466
2,024	187,466
Total	$ 1,124,799

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - CAD ($)	Aug. 31, 2018	Aug. 31, 2017
Payables and Accruals [Abstract]
Trade payables	$ 1,412,277	$ 929,855
Vendor accruals	170,414	145,746
Accounts payable and accrued liabilities	$ 1,582,691	$ 1,075,601

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	12 Months Ended
	Aug. 31, 2018CAD ($)	Aug. 31, 2018USD ($)	Aug. 31, 2017CAD ($)	Aug. 31, 2017USD ($)	Aug. 31, 2016CAD ($)	Aug. 31, 2016USD ($)	Aug. 31, 2018USD ($)	Aug. 31, 2017USD ($)
Unsecured bear interest rate	3.00%						3.00%
Due on demand	$ 219,500
Debt outstanding	12,500
Consulting fees	105,744		$ 82,873		$ 81,929
President [Member]
Advances payable to related parties	232,000		232,000
Interest payable to related parties	32,538		25,578
Reimbursable expenses	15,737		5,329
Consulting fees	181,070		181,070
Due to related party	438,935		271,984
Advanced from related party
Interest expense	6,960		7,000
Consulting fees paid	159,674		163,466		136,665
President [Member] | USD Currency [Member]
Consulting fees		$ 197,522		$ 72,522
Consulting fees paid		125,000		125,000		$ 26,040
Chief Executive Officer [Member]
Advances payable to related parties	51,000
Due to related party	245,564		79,102
Advanced from related party	51,000
Consulting fees paid	159,674		163,466		67,509
Chief Executive Officer [Member] | USD Currency [Member]
Due to related party							$ 188,100	$ 63,100
Consulting fees paid		125,000		125,000		56,040
Major Shareholder [Member]
Advances payable to related parties
Interest payable to related parties			761
Reimbursable expenses
Consulting fees	181,070		181,070
Due to related party	330,688		259,448
Consulting fees paid	65,481		163,466		136,665
Major Shareholder [Member] | USD Currency [Member]
Consulting fees		114,606		62,522
Consulting fees paid		$ 52,083		$ 125,000
Chief Financial Officer [Member]
Due to related party	$ 75,000		$ 75,000
President [Member]
Consulting fees paid					102,870
Major Shareholder [Member]
Consulting fees paid					$ 102,870
Major Shareholder [Member] | USD Currency [Member]
Consulting fees paid						$ 26,040

Advances from Shareholders (Det

Advances from Shareholders (Details Narrative) - CAD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017
Unsecured bear interest rate	3.00%
Shareholder [Member]
Advances payable	$ 145,000	$ 145,000
Unsecured bear interest rate	3.00%
Interest expense	$ 3,589	4,351
Accrued interest payable	$ 16,971	$ 13,382

License Assignment Fee Payable

License Assignment Fee Payable (Details Narrative)	Oct. 01, 2016USD ($)	Aug. 31, 2018CAD ($)	Aug. 31, 2018USD ($)	Aug. 31, 2018USD ($)	Aug. 31, 2017CAD ($)	Aug. 31, 2017USD ($)	Nov. 23, 2016USD ($)
License assignment fee payable		$ 882,257			$ 683,212
Debt interest rate		3.00%		3.00%
Zoran K Corporation [Member]
License assignment fee payable		$ 882,257			$ 683,212		$ 1,000,000
Zoran K Corporation [Member] | USD Currency [Member]
License assignment fee payable				$ 675,800		$ 545,000
Share Exchange Agreement [Member] | Zoran K Corporation [Member]
Debt interest rate		24.00%		24.00%
Interest expense		$ 167,123
Share Exchange Agreement [Member] | Zoran K Corporation [Member] | USD Currency [Member]
License assignment fee payable				$ 1,000,000
Debt periodic payment	$ 50,000
Gross proceeds from sale of stock			$ 1,000,000
Interest expense		$ 130,800

Commitments (Details Narrative)

Commitments (Details Narrative)	Jun. 13, 2016CAD ($)$ / sharesshares	Jun. 13, 2016USD ($)shares	Aug. 31, 2018CAD ($)	Aug. 31, 2017CAD ($)	Aug. 31, 2016CAD ($)	Aug. 24, 2016shares
Premises lease rental			$ 25,918	$ 12,950	$ 13,200
Premises Lease [Member]
Premises lease rental			21,000
Consultant [Member]
Share issued during period | shares	1,000,000	1,000,000
Consultant [Member] | USD Currency [Member]
Share issued during period, value	$ 250,000
MCM Agreement [Member]
Accrued remuneration			80,770	80,770
ZKC Agreement [Member]
Accrued remuneration
Consulting Agreement [Member] | Consultant [Member]
Consulting agreement period	10 years	10 years
Earnings per share | $ / shares	$ 0.05
Share issued during period | shares	20,000,000	20,000,000
Consulting Agreement [Member] | Consultant [Member] | USD Currency [Member]
Remuneration		$ 125,000
Subco [Member]
Preferred stock shares issued | shares						750,000
Edgewater Consulting Corp [Member]
Accrued remuneration			$ 75,000	$ 75,000

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative)		Sep. 21, 2017CAD ($)$ / sharesshares	Sep. 21, 2017CAD ($)$ / sharesshares	Sep. 21, 2017USD ($)shares	Nov. 02, 2016CAD ($)shares	Nov. 02, 2016USD ($)shares	Oct. 31, 2016CAD ($)$ / sharesshares	Oct. 31, 2016USD ($)shares	Aug. 25, 2016	Aug. 24, 2016shares	Jun. 28, 2013shares	Aug. 31, 2018CAD ($)$ / sharesshares	Aug. 31, 2018USD ($)shares	Aug. 31, 2017CAD ($)$ / sharesshares	Aug. 31, 2017USD ($)shares	Aug. 31, 2016CAD ($)shares	Aug. 31, 2018$ / sharesshares	Feb. 28, 2018$ / sharesshares	Sep. 21, 2017$ / shares	Aug. 31, 2017$ / sharesshares	Nov. 02, 2016$ / shares	Oct. 31, 2016$ / shares
Common stock, shares authorized | shares												300,000,000		300,000,000			300,000,000			300,000,000
Reverse stock split									The Company completed a reverse split of the Company’s common stock at the ratio of one new share for every two existing shares. All share and per share amounts have been adjusted to reflect this reverse split.
Common stock, shares issued | shares												57,532,843		56,892,843			57,532,843			56,892,843
Common stock, shares outstanding | shares												57,532,843		56,892,843			57,532,843			56,892,843
Subscriptions were received														$ 395,580
Canadian Financing [Member]
Common stock shares issued during period | shares							140,000	140,000
Shares issued price per share | $ / shares							$ 0.50
Proceeds from issuance of common stock							$ 70,000
Warrants exercise price per share | $ / shares							$ 0.80
Warrant to purchase, shares | shares							1
Common stock allocated value							$ 41,314
Share purchase warrants allocated value							$ 28,686
US Financing [Member]
Common stock shares issued during period | shares					400,000	400,000	220,770	220,770
Proceeds from issuance of common stock					$ 524,230		$ 146,716
Warrant to purchase, shares | shares					1		1					15,000					15,000
Common stock allocated value					$ 286,950		$ 86,027
Share purchase warrants allocated value					$ 237,280		$ 60,689
Finder's fees												$ 19,899
Purchase warrant, value												$ 8,742
Common Stock [Member]
Common shares acquired | shares	[1]															50,000,000
Common stock shares issued during period | shares		10,000	630,000	630,000								5,000	5,000
Shares issued price per share | $ / shares		$ 0.80	$ 0.80
Proceeds from issuance of common stock			$ 830,674												$ 8,000
Warrant to purchase, shares | shares		1	1
Common stock allocated value		$ 491,041	$ 491,041
Share purchase warrants allocated value		$ 339,633	$ 339,633
Finder's fees												$ 6,435
Purchase warrant, value												2,581
Proceeds from exercise of warrants														$ 2,049
Stock Subscriptions [Member]
Shares issued price per share | $ / shares														$ 1
Proceeds from issuance of common stock														$ 838,674
Warrants exercise price per share | $ / shares														$ 1				$ 0.80
Warrant to purchase, shares | shares																		12,500
Subscriptions were received												$ 10,000		$ 838,674
Number of shares subscriptions during the period | shares														630,000	630,000
Common stock subscriptions period														24 months	24 months
Stock Subscriptions [Member] | Private Placement [Member]
Subscriptions were received														$ 8,000
Warrant [Member]
Common stock shares issued during period | shares														10,000	10,000
Shares issued price per share | $ / shares														$ 0.80
Warrants outstanding of weighted-average remaining contractual life												2 months 1 day	2 months 1 day	1 year 2 months 1 day	1 year 2 months 1 day
Tropic Spa Inc [Member] | Common Stock [Member]
Common shares acquired | shares										21,672,623	39,015,439	296,500	296,500
Subco [Member] | Preferred Stock [Member]
Common shares acquired | shares											39,015,439
USD Currency [Member]
Common stock, par share value | $ / shares												$ 0.001
Warrant to purchase, shares | shares												635,000					635,000
USD Currency [Member] | US Financing [Member]
Shares issued price per share | $ / shares																					$ 1	$ 0.50
Proceeds from issuance of common stock						$ 400,000		$ 110,385
Warrants exercise price per share | $ / shares																	$ 1.40				$ 1.40	$ 0.80
USD Currency [Member] | Common Stock [Member]
Shares issued price per share | $ / shares																			$ 1
Proceeds from issuance of common stock				$ 630,000
Warrants exercise price per share | $ / shares																	$ 1.40		$ 1.40
Finder's fees													$ 5,000
USD Currency [Member] | Stock Subscriptions [Member]
Common stock exercisable price per share | $ / shares																				$ 1.40
USD Currency [Member] | Stock Subscriptions [Member] | Private Placement [Member]
Subscriptions were received															$ 630,000
USD Currency [Member] | Warrant [Member]
Warrants outstanding of weighted-average remaining contractual life												7 months 2 days	7 months 2 days	1 year 2 months 1 day	1 year 2 months 1 day
[1]	The above presentation reflects a 1:2 reverse split of the Company's common stock on August 25, 2016. See Note 16.

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Stock Purchase Warrants (Details) - $ / shares	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Aug. 31, 2016
USD Currency [Member]
Stock Purchase Warrants Issued, Shares	635,000
Stock Purchase Warrants Outstanding, Shares	1,270,770	635,700
October 31, 2018 [Member]
Stock Purchase Warrants Price Per Share	$ 0.80
Stock Purchase Warrants Issued, Shares
Stock Purchase Warrants Outstanding, Shares	117,500	130,000
Exercised	(12,500)
October 31, 2018 [Member] | USD Currency [Member]
Stock Purchase Warrants Price Per Share	$ 0.80
Stock Purchase Warrants Issued, Shares
Stock Purchase Warrants Outstanding, Shares	220,770	220,700
Exercised
September 30, 2018 - Finder [Member] | USD Currency [Member]
Stock Purchase Warrants Price Per Share	$ 1.40
Stock Purchase Warrants Issued, Shares
Stock Purchase Warrants Outstanding, Shares	15,000	15,000
Exercised
November 2, 2018 [Member] | USD Currency [Member]
Stock Purchase Warrants Price Per Share	$ 1.40
Stock Purchase Warrants Issued, Shares
Stock Purchase Warrants Outstanding, Shares	400,000	400,000
Exercised
July 17,2019 - Finder [Member] | USD Currency [Member]
Stock Purchase Warrants Price Per Share	$ 1.40
Stock Purchase Warrants Issued, Shares	5,000
Stock Purchase Warrants Outstanding, Shares	5,000
Exercised
September 7, 2019 | USD Currency [Member]
Stock Purchase Warrants Price Per Share	$ 1.40
Stock Purchase Warrants Issued, Shares	630,000
Stock Purchase Warrants Outstanding, Shares	630,000
Exercised

Stockholders' Deficiency - Sc_2

Stockholders' Deficiency - Schedule of Stock Options Valuation Assumptions (Details) - Warrant [Member]	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	100.00%	100.00%
Expected life of warrants		2 years
Minimum [Member]
Risk-free interest rate	1.47%	0.54%
Expected life of warrants	29 days
Maximum [Member]
Risk-free interest rate	2.04%	0.55%
Expected life of warrants	2 years

Taxes (Details Narrative)

Taxes (Details Narrative)	12 Months Ended
	Aug. 31, 2018CAD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards net	$ 7,844,000
Operating loss carryforwards expiration year	expiring from 2024 to 2038

Taxes - Schedule of Deferred Ta

Taxes - Schedule of Deferred Tax Assets (Details) - CAD ($)	12 Months Ended
	Aug. 31, 2018		Aug. 31, 2017		Aug. 31, 2016
Income Tax Disclosure [Abstract]
Net loss before income taxes	$ (810,825)		$ (5,071,687)		$ (1,030,293)
Tax rate		[1]		[2]		[2]
Calculated income tax recovery	$ (199,277)		$ (1,391,061)		$ (273,260)
Adjustment for deductible and non-deductible amounts	(77,794)		1,130,327		48,858
Unrecognized benefit of non-capital losses	277,071		260,734		224,402
Income tax recovery
[1]	Canada - 26.50%; United States - 21%
[2]	Canada - 26.50%; United States - 34%

Taxes - Schedule of Deferred _2

Taxes - Schedule of Deferred Tax Assets (Details) (Parenthetical)	12 Months Ended
	Aug. 31, 2018		Aug. 31, 2017		Aug. 31, 2016
Tax rate		[1]		[2]		[2]
Canada [Member]
Tax rate	26.50%		26.50%		26.50%
United States [Member]
Tax rate	21.00%		34.00%		34.00%
[1]	Canada - 26.50%; United States - 21%
[2]	Canada - 26.50%; United States - 34%

Taxes - Schedule of Statutory I

Taxes - Schedule of Statutory Income Tax Rate (Details) - CAD ($)	Aug. 31, 2018	Aug. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 2,029,000	$ 1,784,000
Temporary deductible differences (net)	753,000	834,000
Gross deferred tax assets	2,782,000	2,618,000
Valuation allowance	(2,782,000)	(2,618,000)
Net deferred tax assets

Contingent Liability (Details N

Contingent Liability (Details Narrative) - shares		Aug. 24, 2016	Jun. 28, 2013	Aug. 31, 2018	Aug. 31, 2016
Common Stock [Member]
Common shares acquired	[1]				50,000,000
Tropic Spa Inc [Member] | Common Stock [Member]
Common shares acquired		21,672,623	39,015,439	296,500
Subco [Member]
Preferred stock outstanding				50,000,000
Subco [Member] | Preferred Stock [Member]
Common shares acquired			39,015,439
Number of preferred stock for exchange		10,836,312	39,015,439	148,250
[1]	The above presentation reflects a 1:2 reverse split of the Company's common stock on August 25, 2016. See Note 16.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Nov. 02, 2018$ / sharesshares	Oct. 31, 2018CAD ($)shares	Oct. 31, 2018$ / shares	Oct. 09, 2018shares	Sep. 30, 2018CAD ($)shares	Sep. 30, 2018$ / shares	Aug. 31, 2018shares	Aug. 31, 2017shares
Common stock, shares authorized							300,000,000	300,000,000
Subsequent Event [Member]
Warrants to purchase common stock	400,000				15,000
Common stock, shares authorized				500,000,000
Subsequent Event [Member] | CEO [Member]
Advances from CEO | $		$ 5,000			$ 20,000
Subsequent Event [Member] | Warrant One [Member]
Warrants to purchase common stock		220,770
Subsequent Event [Member] | Warrant Two [Member]
Warrants to purchase common stock		117,500
Subsequent Event [Member] | USD [Member]
Warrants exercise price | $ / shares	$ 1.40					$ 1.40
Subsequent Event [Member] | USD [Member] | Warrant One [Member]
Warrants exercise price | $ / shares			$ 0.80
Subsequent Event [Member] | USD [Member] | Warrant Two [Member]
Warrants exercise price | $ / shares			$ 0.80